Non-Hodgkin Lymphoma by Clinical Course

Observed

← altered in cohorts of

VPS35

67 / 263 cases (25 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ORC6

66 / 263 cases (25 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

TPTE

66 / 263 cases (25 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

KMT2D

247 / 1,001 cases (25 %) · ssm · dlbcl_duke_2017 · largest of 2 cohorts

—

Observed

← altered in cohorts of

PCLO

32 / 135 cases (24 %) · ssm · dlbcl_dfci_2018

—

Observed

← altered in cohorts of

MYLK3

62 / 263 cases (24 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

IGLL5

60 / 263 cases (23 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

C16orf87

56 / 263 cases (21 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

PTPRC

50 / 263 cases (19 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

BTG1

25 / 135 cases (19 %) · ssm · dlbcl_dfci_2018

—

Observed

← altered in cohorts of

ZNF280B

48 / 263 cases (18 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ZNF280A

47 / 263 cases (18 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

GGTLC2

46 / 263 cases (17 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

PRAME

46 / 263 cases (17 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

MYD88

172 / 1,001 cases (17 %) · ssm · dlbcl_duke_2017 · largest of 2 cohorts

—

Observed

← altered in cohorts of

MYC

45 / 263 cases (17 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

OR11H12

44 / 263 cases (17 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ATP6V1G3

43 / 263 cases (16 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SLAMF6

43 / 263 cases (16 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CD84

40 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ENSA

40 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ADAMTSL4

39 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

C1orf56

39 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CD48

39 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CDC42SE1

39 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

GABPB2

39 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

GOLPH3L

39 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

MLLT11

39 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

TARS2

39 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CD79B

20 / 135 cases (15 %) · ssm · dlbcl_dfci_2018

—

Observed

← altered in cohorts of

FAT4

20 / 135 cases (15 %) · ssm · dlbcl_dfci_2018

—

Observed

← altered in cohorts of

PIM1

147 / 1,001 cases (15 %) · ssm · dlbcl_duke_2017 · largest of 2 cohorts

—

Observed

← altered in cohorts of

ANXA9

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ARNT

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

BNIPL

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CTSK

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CTSS

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CTXND2

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ECM1

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

FAM243B

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

HORMAD1

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

KCNE1B

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

MCL1

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

MINDY1

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

PRUNE1

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SLAMF1

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SLAMF7

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SMIM11B

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SMIM34B

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CERS2

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

GPT2

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

LYSMD1

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

RPRD2

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SCNM1

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SEMA6C

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SETDB1

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

TMOD4

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

TNFAIP8L2

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

VANGL2

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

VPS72

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

FCRL4

36 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

NEK7

36 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

PIP5K1A

36 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

PRPF3

36 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

APH1A

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

C1orf54

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CA14

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CIART

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

FCRL1

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

FCRL2

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

FCRL3

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

FCRL5

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

MRPS21

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

NCSTN

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

NHLH1

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SERPINC1

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SYT11

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

GPR52

34 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

RABGAP1L

34 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

RC3H1

34 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ANP32E

33 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CD5L

33 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

COPA

33 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

DARS2

33 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

GON4L

33 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

PGM5

33 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

PSMD4

33 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ZBTB37

33 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

APOA2

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

DAP3

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

DCAF8

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

DNAJA2

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

FCER1G

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

LY9

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

MSTO1

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

NR1I3

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

PEX19

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

RCSD1

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

TMEM252

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

TOMM40L

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

YY1AP1

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ZNF687

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CD244

31 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ITLN1

31 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

USP21

31 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CREBBP

115 / 1,001 cases (11 %) · ssm · dlbcl_duke_2017 · largest of 2 cohorts

—

Observed

← altered in cohorts of

H1-4

105 / 1,001 cases (10 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

BCL2

101 / 1,001 cases (10 %) · ssm · dlbcl_duke_2017 · largest of 2 cohorts

—

Observed

← altered in cohorts of

SPEN

101 / 1,001 cases (10 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

ARID1A

96 / 1,001 cases (9.6 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

TP53

93 / 1,001 cases (9.3 %) · ssm · dlbcl_duke_2017 · largest of 2 cohorts

—

Observed

← altered in cohorts of

SOCS1

92 / 1,001 cases (9.2 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

CARD11

89 / 1,001 cases (8.9 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

ARID1B

83 / 1,001 cases (8.3 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

GNA13

83 / 1,001 cases (8.3 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

SETD1B

83 / 1,001 cases (8.3 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

TNFRSF14

79 / 1,001 cases (7.9 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

DUSP2

76 / 1,001 cases (7.6 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

MGA

75 / 1,001 cases (7.5 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

SMARCA4

75 / 1,001 cases (7.5 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

NOTCH2

73 / 1,001 cases (7.3 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

ATM

72 / 1,001 cases (7.2 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

ZNF608

68 / 1,001 cases (6.8 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

KLHL6

67 / 1,001 cases (6.7 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

SGK1

67 / 1,001 cases (6.7 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

BIRC6

64 / 1,001 cases (6.4 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

IRF8

64 / 1,001 cases (6.4 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

MTOR

64 / 1,001 cases (6.4 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

PIK3CD

63 / 1,001 cases (6.3 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

SETD2

62 / 1,001 cases (6.2 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

TET2

62 / 1,001 cases (6.2 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

EZH2

61 / 1,001 cases (6.1 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

ZNF292

59 / 1,001 cases (5.9 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

BTG2

58 / 1,001 cases (5.8 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

EP300

57 / 1,001 cases (5.7 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

B2M

56 / 1,001 cases (5.6 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

CD70

56 / 1,001 cases (5.6 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

KMT2C

56 / 1,001 cases (5.6 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

MEF2B

55 / 1,001 cases (5.5 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

STAT6

53 / 1,001 cases (5.3 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

TBL1XR1

53 / 1,001 cases (5.3 %) · ssm · dlbcl_duke_2017

—

Observed

← altered in cohorts of

KLHL14

52 / 1,001 cases (5.2 %) · ssm · dlbcl_duke_2017

—

Observed

Non-Hodgkin Lymphoma by Clinical Course investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 154show all (up to 200)
→ investigated in trials for	Rituximabmonoclonal antibody 194 trials (61 active) · roll-up of the cancer and its descendants	—	—	Non-Hodgkin Lymphoma by Clinical Course	194	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 147 trials (53 active) · roll-up of the cancer and its descendants	—	—	Non-Hodgkin Lymphoma by Clinical Course	147	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 89 trials (24 active) · roll-up of the cancer and its descendants	—	—	Non-Hodgkin Lymphoma by Clinical Course	89	Observed	clinicaltrials	graph →
→ investigated in trials for	Vincristinesmall molecule 73 trials (25 active) · roll-up of the cancer and its descendants	—	—	Non-Hodgkin Lymphoma by Clinical Course	73	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 70 trials (21 active) · roll-up of the cancer and its descendants	—	—	Non-Hodgkin Lymphoma by Clinical Course	70	Observed	clinicaltrials	graph →
→ investigated in trials for	Prednisonesmall molecule 68 trials (29 active) · roll-up of the cancer and its descendants	—	—	Non-Hodgkin Lymphoma by Clinical Course	68	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 64 trials (24 active) · roll-up of the cancer and its descendants	—	—	Non-Hodgkin Lymphoma by Clinical Course	64	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenalidomidesmall molecule 59 trials (24 active) · roll-up of the cancer and its descendants	—	—	Non-Hodgkin Lymphoma by Clinical Course	59	Observed	clinicaltrials	graph →
→ investigated in trials for	Dexamethasonesmall molecule 46 trials (14 active) · roll-up of the cancer and its descendants	—	—	Non-Hodgkin Lymphoma by Clinical Course	46	Observed	clinicaltrials	graph →
→ investigated in trials for	Ibrutinibsmall molecule 40 trials (18 active) · roll-up of the cancer and its descendants	—	—	Non-Hodgkin Lymphoma by Clinical Course	40	Observed	clinicaltrials	graph →
→ investigated in trials for	Methotrexatesmall molecule 39 trials (10 active) · roll-up of the cancer and its descendants	—	—	Non-Hodgkin Lymphoma by Clinical Course	39	Observed	clinicaltrials	graph →
→ investigated in trials for	Bortezomibsmall molecule 38 trials (3 active) · roll-up of the cancer and its descendants	—	—	Non-Hodgkin Lymphoma by Clinical Course	38	Observed	clinicaltrials	graph →
→ investigated in trials for	Cytarabinesmall molecule 35 trials (12 active) · roll-up of the cancer and its descendants	—	—	Non-Hodgkin Lymphoma by Clinical Course	35	Observed	clinicaltrials	graph →
→ investigated in trials for	Bendamustinesmall molecule 34 trials (12 active) · roll-up of the cancer and its descendants	—	—	Non-Hodgkin Lymphoma by Clinical Course	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Obinutuzumabmonoclonal antibody 34 trials (16 active) · roll-up of the cancer and its descendants	—	—	Non-Hodgkin Lymphoma by Clinical Course	34	Observed	clinicaltrials	graph →

Non-Hodgkin Lymphoma by Clinical Course investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 154show all (up to 200)

→ investigated in trials for

Rituximabmonoclonal antibody

194 trials (61 active) · roll-up of the cancer and its descendants

—

194

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

147 trials (53 active) · roll-up of the cancer and its descendants

—

147

Observed

→ investigated in trials for

Fludarabinesmall molecule

89 trials (24 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vincristinesmall molecule

73 trials (25 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Etoposidesmall molecule

70 trials (21 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Prednisonesmall molecule

68 trials (29 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall molecule

64 trials (24 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lenalidomidesmall molecule

59 trials (24 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dexamethasonesmall molecule

46 trials (14 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ibrutinibsmall molecule

40 trials (18 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Methotrexatesmall molecule

39 trials (10 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bortezomibsmall molecule

38 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cytarabinesmall molecule

35 trials (12 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bendamustinesmall molecule

34 trials (12 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Obinutuzumabmonoclonal antibody

34 trials (16 active) · roll-up of the cancer and its descendants

—

Observed

Aggressive Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma by Clinical Course studied in …STUDIED_INderived10 of 1,200show all (up to 200)
→ studied in	NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active)	—	—	Aggressive Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06649812Phase 2 · recruiting Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active)	—	—	Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type	1	Observed	clinicaltrials	graph →
→ studied in	NCT07583810Phase 2 · recruiting Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active)	—	—	Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00923507recruiting Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active)	—	—	Waldenstrom Macroglobulinemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT01676805recruiting Tissue Collection for Studies of Lymph Cancer · condition mapped ALIAS · 1,200 trials mapped (405 active)	—	—	Adult T-Cell Leukemia/Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02682667recruiting Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols · condition mapped ALIAS · 1,200 trials mapped (405 active)	—	—	Adult T-Cell Leukemia/Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03223610Phase 1/Phase 2 · recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active)	—	—	Burkitt Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05006716Phase 1/Phase 2 · recruiting A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active)	—	—	Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05100862Phase 3 · active not recruiting A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active)	—	—	Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06350318Phase 2 · recruiting Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active)	—	—	Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →

Non-Hodgkin Lymphoma by Clinical Course studied in …STUDIED_INderived10 of 1,200show all (up to 200)

→ studied in

NCT04231877Phase 1 · active not recruiting

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active)

—

Observed

Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type

→ studied in

NCT06649812Phase 2 · recruiting

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active)

—

Observed

Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma

→ studied in

NCT07583810Phase 2 · recruiting

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active)

—

Observed

Waldenstrom Macroglobulinemia

→ studied in

NCT00923507recruiting

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active)

—

Observed

Adult T-Cell Leukemia/Lymphoma

→ studied in

NCT01676805recruiting

Tissue Collection for Studies of Lymph Cancer · condition mapped ALIAS · 1,200 trials mapped (405 active)

—

Observed

Adult T-Cell Leukemia/Lymphoma

→ studied in

NCT02682667recruiting

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols · condition mapped ALIAS · 1,200 trials mapped (405 active)

—

Observed

→ studied in

NCT03223610Phase 1/Phase 2 · recruiting

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active)

—

Observed

→ studied in

NCT05006716Phase 1/Phase 2 · recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active)

—

Marginal Zone Lymphoma

Observed

→ studied in

NCT05100862Phase 3 · active not recruiting

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active)

—

Marginal Zone Lymphoma

Observed

→ studied in

NCT06350318Phase 2 · recruiting

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active)

—

Marginal Zone Lymphoma

Observed